Drug Database
Back to search

Netherlands· NL-3634c2a1cdce

Oncaspar 750 E/ml, oplossing voor injectie/infusie

A pegaspargase product containing pegaspargase, registered in Netherlands by Les Laboratoires Servier. The same ATC class is registered in 15 of our 19 countries.

ATC L01XX24

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOncaspar 750 E/ml, oplossing voor inj…ATCL01XX24REGISTER NO.NL-3634c2a1cdcePACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about pegaspargaseAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Pegaspargase is registered in 15 of 19 countries.

Countries holding a registration under ATC L01XX24 (pegaspargase), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search pegaspargase products by name

Pegaspargase · ATC L01XX24

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
PEGASPARGASE
Manufacturer
Les Laboratoires Servier
Country
Netherlands (NL)
ATC code
L01XX24
ATC class
Pegaspargase
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/15/1070

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

441 interactions on record for pegaspargase.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check pegaspargase against other medicinesHow interaction checks work

Pegaspargase · interactions on record

441 records

  • 30 severe
  • 411 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ClotrimazoleA01AB18moderate
  • Chenodeoxycholic acidA05AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pegaspargase in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pegaspargase products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Oncaspar
  • Liechtenstein · Oncaspar
  • Norway · Oncaspar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e8eff5aa-3f52-41c9-b0d8-4a6dff3b521a
GET /v1/drugs/e8eff5aa-3f52-41c9-b0d8-4a6dff3b521a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie of infusie",
  "route": "Intramusculair gebruik, Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/oncaspar-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Pegaspargase",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp115910",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "PEGASPARGASE"
  ],
  "leaflet_url": null,
  "authorised_at": "2016/01/14",
  "procedure_number": "EMEA/H/C/003789",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/15/1070",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about pegaspargase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console